Form 4: Boston Scientific EVP Joseph Fitzgerald Executes Stock Options and Sells Shares Under 10b5-1 Plan

Executive Vice President of Boston Scientific, Joseph Michael Fitzgerald, exercised stock options and sold shares of common stock under a pre-established Rule 10b5-1 trading plan.

Summary

• Joseph Michael Fitzgerald, an Executive Vice President at Boston Scientific, reported transactions involving the company's common stock on October 7, 2024.
• Fitzgerald exercised stock options to acquire 59,021 shares at $17.26 and 57,618 shares at $24.98.
• He then sold 132,527 shares at a weighted average price of $85.0007, with individual sales ranging from $85.00 to $85.01.
• These transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on May 23, 2024.
• Following these transactions, Fitzgerald directly owns 160,467 shares of Boston Scientific common stock.
• He also indirectly owns 4,894 shares through his child, but disclaims beneficial ownership of these shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports transactions under a pre-existing plan, which is a common and regulated practice. There's no inherent positive or negative signal.

Positives

• The transactions were executed under a pre-established 10b5-1 trading plan, which can mitigate concerns about insider trading.
• The executive still holds a significant number of shares after the sale, indicating continued alignment with the company's performance.

Negatives

• The sale of shares by an executive could be perceived negatively by some investors, although the 10b5-1 plan provides context.

Risks

• While the 10b5-1 plan provides a framework, large sales by executives can still create short-term price volatility.
• Investor sentiment could be affected if there are concerns about the reasons behind the stock sales, even with the pre-established plan.

Industry Context

Executive stock transactions are common and closely monitored in the medical device industry. Rule 10b5-1 plans are frequently used to allow insiders to sell shares without raising concerns about insider trading.

Comparison to Industry Standards

• Executive compensation practices, including stock options and sales, are standard across large medical device companies like Medtronic, Abbott, and Stryker.
• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their stock holdings in a compliant manner.
• The reported transactions are typical in terms of the types of securities involved (common stock and stock options) and the reporting requirements (Form 4 filing).

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the potential for short-term price fluctuations.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates